Search results

Filter (4 in use)

Type 1 selected

  • Remove filter for Guidance (1)

Status

  • Filter by Published (1)

Last updated 1 selected

  • Remove filter for Last 3 months
  • Filter by Last 6 months
  • Filter by Last year
  • Filter by Last 3 years

Guidance programme 2 selected

  • Filter by Technology appraisal guidance (16)
  • Filter by NICE guidelines (15)
  • Filter by Clinical guidelines (10)
  • Filter by COVID-19 rapid guidelines (4)
  • Filter by Interventional procedures guidance (4)
  • Filter by Medical technologies guidance (2)
  • Filter by Antimicrobial prescribing guidelines (1)
  • Filter by Diagnostics guidance (1)
  • Remove filter for Highly specialised technologies guidance (1)
  • Remove filter for Safe staffing guidelines

1 result

Sorted by Date . | Sort by Relevance

  • Guidance Remove Guidance filter
  • Last 3 months Remove Last 3 months filter
  • Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
  • Safe staffing guidelines Remove Safe staffing guidelines filter
  1. Volanesorsen for treating familial chylomicronaemia syndrome (HST13)

    Evidence-based recommendations on volanesorsen (Waylivra) for treating familial chylomicronaemia syndrome in adults

    Type
    Highly specialised technologies guidance
    Published
    21 October 2020
    View recommendations for HST13
    Show all sections for HST13

    Sections for HST13

    1. Overview
    2. 1 Recommendations
    3. 2 The condition
    4. 3 The technology
    5. 4 Consideration of the evidence
    6. 5 Implementation
    7. 6 Evaluation committee members and NICE project team